On June 30, Guangdong True Health Medical Technology Development Co., Ltd., a local enterprise of the Guangdong-Macao In-Depth Cooperation Zone in Hengqin, was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 02697.HK), becoming China's "first listed firm specializing in puncture surgical robots."
This also marks the first Macao-founded biopharmaceutical company to go public. The Initial Public Offering (IPO) is expected to raise approximately 100 million US dollars, with proceeds to be used for product R&D and capacity expansion.
The company was founded by a Macao entrepreneur and settled in Hengqin in 2023. It owns China's first self-developed puncture surgery navigation and positioning system and the world's first navigation and positioning microwave ablation system. It also holds 15 medical device registration certificates.
Taking up 36.4% domestic market share in China, its products rank first in the industry and have been adopted by nearly 100 hospitals, with over 7,200 surgeries completed cumulatively.
After the listing, Guangdong True Health Medical Technology Development Co., Ltd. plans to obtain CE marking (Conformité Européenne) by the end of 2026 and tap into markets across European and Portuguese-speaking countries.
This listing is an important milestone for Hengqin's biopharmaceutical industry. The Cooperation Zone currently has over 40 companies in the IPO pipeline. It will further improve the supporting infrastructure for the big health industry, nurture technology-driven, innovative enterprises, and advance diversified industrial development in both Hengqin and Macao.
Reporter | Huang Xinyi
Photo | Hengqin Online
